Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.60
- Piotroski Score 4.00
- Grade Buy
- Symbol (NVCR)
- Company NovoCure Limited
- Price $17.65
- Changes Percentage (-2.49%)
- Change -$0.45
- Day Low $17.31
- Day High $18.10
- Year High $24.74
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $36.00
- High Stock Price Target $200.00
- Low Stock Price Target $14.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.81
- Trailing P/E Ratio -11.88
- Forward P/E Ratio -11.88
- P/E Growth -11.88
- Net Income $-207,043,000
Income Statement
Quarterly
Annual
Latest News of NVCR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Even after rising 8.9% this past week, NovoCure (NASDAQ:NVCR) shareholders are still down 86% over the past three years
NovoCure Limited's stock price has recently surged by 40% in three months, showing a positive trend. However, over the past three years, the stock has plummeted by 86%....
By Yahoo! Finance | 3 months ago -
NovoCure Limited (NVCR) Stock Price, News, Quote & History - Yahoo Finance
Novocure shared promising results from the TIGER study on TTFields therapy for glioblastoma. The study included 429 patients in Germany, making it the largest non-interventional research on this treat...
By Yahoo! Finance | 4 months ago
